Serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels are regulated by growth hormone, nutritional status, and other endocrine factors, and are implicated in aging, metabolic disorders, and malignancies. Establishing appropriate reference ranges for these biomarkers is essential for safety monitoring and pharmacodynamic assessments in clinical trials. Although various detection methods—including enzyme-linked immunosorbent assay, chemiluminescence immunoassay, radioimmunoassay, and immunoradiometric assay (IRMA)—are available, defining reliable reference intervals remains challenging due to variability linked to age, sex, season, and assay methodology. IRMA manufacturers typically provide generalized reference values and recommend that laboratories establish context-specific ranges; however, data from healthy adult populations are limited. We analyzed data from 255 self-reported healthy Korean men aged 19–40 years using the IRMA method and R software. Age-specific reference ranges and standardized centile curves for serum IGF-1 and IGFBP-3 were established. Both biomarkers demonstrated significant seasonal variation, with notable differences observed among spring, autumn, and winter groups. This study presents a method for establishing institution-specific reference ranges and highlights the importance of considering seasonal variations to help reduce unnecessary dropouts during clinical trials.
30 October 2026 in Clinical and Translational Science
Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker characterized by rapid onset and sustained acid suppression. This study aimed to evaluate the effect of food on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zastaprazan in healthy participants. In this randomized, open‐label, two‐period crossover phase 1 study, 24 healthy participants received a single oral dose of zastaprazan 20 mg under fasted and fed conditions. PK parameters were evaluated using noncompartmental analysis, and PD effects were assessed through continuous intragastric pH monitoring. Under fed conditions, peak exposure (Cmax) decreased (geometric mean ratio [GMR], 0.6997; 90% confidence interval [CI], 0.6292–0.7781), whereas systemic exposure (AUC last ) increased (GMR, 1.3783; 90% CI, 1.2688–1.4973), accompanied by a delayed T max . Despite these PK differences, PD outcomes were comparable between fed and fasted conditions. The percentage of time with intragastric pH ≥ 4 over 24 h was similar under fed and fasted conditions (70.01% vs. 69.19%), with no meaningful differences observed in other pH‐based parameters. Zastaprazan was well tolerated, and no clinically significant safety concerns were identified. Food altered the rate and extent of zastaprazan absorption but did not affect its PD response. These findings indicate that food‐related PK changes do not meaningfully affect PD outcomes and support the administration of zastaprazan without regard to meals. This flexibility may enhance its clinical utility as an acid‐suppressive therapy. Trial Registration: The study was registered at ClinicalTrials.gov (NCT05712681)